Demant Receivables 2012-2023 | WILYY

Demant receivables for the quarter ending December 31, 2023 were $0.646B, a 3.61% increase year-over-year.

  • Demant receivables for 2023 were $0.646B, a 6.22% increase from 2022.
  • Demant receivables for 2022 were $0.609B, a 5.17% decline from 2021.
  • Demant receivables for 2021 were $0.642B, a 22.39% increase from 2020.

Demant Receivables 2012-2023 | WILYY

  • Demant receivables for 2023 were $0.646B, a 6.22% increase from 2022.
  • Demant receivables for 2022 were $0.609B, a 5.17% decline from 2021.
  • Demant receivables for 2021 were $0.642B, a 22.39% increase from 2020.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$194.8B
Boston Scientific (BSX)$139.8B
Stryker (SYK)$139.4B
EssilorLuxottica (ESLOY)$110.1B
Medtronic (MDT)$103.4B
Lonza Group Ag (LZAGY)$43.7B
Haleon (HLN)$41.2B
GE HealthCare Technologies (GEHC)$38.7B
ResMed (RMD)$34.3B
Terumo (TRUMY)$28B
Koninklijke Philips (PHG)$24.3B
Zimmer Biomet Holdings (ZBH)$20.8B
Insulet (PODD)$19.1B
Baxter (BAX)$15B
Smith & Nephew SNATS (SNN)$10.5B
Bio-Rad Laboratories (BIO)$9.6B
BellRing Brands (BRBR)$9.1B
Lantheus Holdings (LNTH)$6.7B
Haemonetics (HAE)$3.9B
ICU Medical (ICUI)$3.8B
Prestige Consumer Healthcare (PBH)$3.7B
Perrigo (PRGO)$3.3B
Envista Holdings (NVST)$3.2B
QuidelOrtho (QDEL)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
Neogen (NEOG)$2.7B
GN Store Nord (GNNDY)$2.6B
LeMaitre Vascular (LMAT)$2.1B
Green Thumb Industries (GTBIF)$1.6B
AtriCure (ATRC)$1.5B